Treatment of gastro-esophageal reflux disease: The new kids to block: VIEWPOINT

Neurogastroenterology and Motility

Volumn 22, Issue 8, 2010, Pages 836-840

  Blondeau, K ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

lower esophageal sphincter; refractory gastro esophageal reflux disease; treatment

Indexed keywords

4 AMINOBUTYRIC ACID B RECEPTOR BLOCKING AGENT; 4 AMINOBUTYRIC ACID RECEPTOR STIMULATING AGENT; ADX 10059; AFQ 056; ARBACLOFEN PLACARBIL; AZD 2516; AZD 9343; BACLOFEN; CANNABINOID 1 RECEPTOR AGONIST; CANNABINOID 1 RECEPTOR ANTAGONIST; DRONABINOL; ITOPRIDE; LESOGABERAN; METABOTROPIC RECEPTOR ANTAGONIST; PROTON PUMP INHIBITOR; RIMONABANT; UNCLASSIFIED DRUG;

CLINICAL RESEARCH; CLINICAL TRIAL; DIZZINESS; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; GASTROESOPHAGEAL REFLUX; HEARTBURN; HUMAN; LOWER ESOPHAGUS SPHINCTER; MUSCLE RELAXATION; NAUSEA; NONHUMAN; PARESTHESIA; PRIORITY JOURNAL; REVIEW; SOMNOLENCE; UNSPECIFIED SIDE EFFECT; VOMITING;

ESOPHAGEAL SPHINCTER, LOWER; GABA-B RECEPTOR AGONISTS; GASTROESOPHAGEAL REFLUX; HUMANS; PROTON PUMP INHIBITORS; RECEPTORS, CANNABINOID; RECEPTORS, METABOTROPIC GLUTAMATE;

EID: 77954442076     PISSN: 13501925     EISSN: 13652982     Source Type: Journal    
DOI: 10.1111/j.1365-2982.2010.01537.x     Document Type: Review

References (37)

1. Vakil N, van Zanten SV, Kahrilas P, Dent J, Jones R. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol 2006 101 : 1900 1920.
2. Fass R, Mackel C, Sampliner RE. 24-hour pH monitoring in symptomatic patients without erosive esophagitis who did not respond to antireflux treatment. J Clin Gastroenterol 1994 19 : 97 9.
3. Holloway RH, Dent J, Narielvala F, Mackinnon AM. Relation between oesophageal acid exposure and healing of oesophagitis with omeprazole in patients with severe reflux oesophagitis. Gut 1996 38 : 649 654.
4. Katzka DA, Paoletti V, Leite L, Castell DO. Prolonged ambulatory pH monitoring in patients with persistent gastroesophageal reflux disease symptoms: testing while on therapy identifies the need for more aggressive anti-reflux therapy. Am J Gastroenterol 1996 91 : 2110 2113.
5. Klinkenberg-Knol EC, Meuwissen SG. Combined gastric and oesophageal 24-hour pH monitoring and oesophageal manometry in patients with reflux disease, resistant to treatment with omeprazole. Aliment Pharmacol Ther 1990 4 : 485 495.
6. Boeckxstaens GE. The lower oesophageal sphincter. Neurogastroenterol Motil 2005 17 (Suppl. 1 13 21.
7. Kahrilas PJ, Quigley EM, Castell DO, Spechler SJ. The effects of tegaserod (HTF 919) on oesophageal acid exposure in gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2000 14 : 1503 1509.
8. Tutuian R, Mainie I, Allan R et al. Effects of a 5-HT(4) receptor agonist on oesophageal function and gastro-oesophageal reflux: studies using combined impedance-manometry and combined impedance-pH. Aliment Pharmacol Ther 2006 24 : 155 162.
9. Kim YS, Kim TH, Choi CS et al. Effect of itopride, a new prokinetic, in patients with mild GERD: a pilot study. World J Gastroenterol 2005 11 : 4210 4214.
10. Scarpellini E, Vos R, Vanden BP, Tack J. Influence of Itopride on esophageal function in man. Gastroenterology 2009 136 (Suppl. 1 A 122.
11. McDermott CM, Abrahams TP, Partosoedarso E et al. Site of action of GABA(B) receptor for vagal motor control of the lower esophageal sphincter in ferrets and rats. Gastroenterology 2001 120 : 1749 1762.
12. Blackshaw LA, Staunton E, Lehmann A, Dent J. Inhibition of transient LES relaxations and reflux in ferrets by GABA receptor agonists. Am J Physiol 1999 277 : G867 74.
13. Lehmann A, Antonsson M, Bremner-Danielsen M, Flardh M, Hansson-Branden L, Karrberg L. Activation of the GABA(B) receptor inhibits transient lower esophageal sphincter relaxations in dogs. Gastroenterology 1999 117 : 1147 1154.
14. Lehmann A, Hansson-Branden L, Karrberg L. Effects of repeated administration of baclofen on transient lower esophageal sphincter relaxation in the dog. Eur J Pharmacol 2000 403 : 163 167.
15. Cange L, Johnsson E, Rydholm H et al. Baclofen-mediated gastro-oesophageal acid reflux control in patients with established reflux disease. Aliment Pharmacol Ther 2002 16 : 869 873.
16. Ciccaglione AF, Marzio L. Effect of acute and chronic administration of the GABA B agonist baclofen on 24 hour pH metry and symptoms in control subjects and in patients with gastro-oesophageal reflux disease. Gut 2003 52 : 464 470.
17. Lidums I, Lehmann A, Checklin H, Dent J, Holloway RH. Control of transient lower esophageal sphincter relaxations and reflux by the GABA(B) agonist baclofen in normal subjects. Gastroenterology 2000 118 : 7 13.
18. Van Herwaarden MA, Samsom M, Rydholm H, Smout AJ. The effect of baclofen on gastro-oesophageal reflux, lower oesophageal sphincter function and reflux symptoms in patients with reflux disease. Aliment Pharmacol Ther 2002 16 : 1655 1662.
19. Vela MF, Tutuian R, Katz PO, Castell DO. Baclofen decreases acid and non-acid post-prandial gastro-oesophageal reflux measured by combined multichannel intraluminal impedance and pH. Aliment Pharmacol Ther 2003 17 : 243 251.
20. Koek GH, Sifrim D, Lerut T, Janssens J, Tack J. Effect of the GABA(B) agonist baclofen in patients with symptoms and duodeno-gastro-oesophageal reflux refractory to proton pump inhibitors. Gut 2003 52 : 1397 1402.
21. Beaumont H, Boeckxstaens GE. Does the presence of a hiatal hernia affect the efficacy of the reflux inhibitor baclofen during add-on therapy? Am J Gastroenterol 2009 104 : 1764 1771.
22. Omari TI, Benninga MA, Sansom L, Butler RN, Dent J, Davidson GP. Effect of baclofen on esophagogastric motility and gastroesophageal reflux in children with gastroesophageal reflux disease: a randomized controlled trial. J Pediatr 2006 149 : 468 474.
23. Gerson LB, Huff FJ, Hila A et al. Arbaclofen placarbil decreases postprandial reflux in patients with gastroesophageal reflux disease. Am J Gastroenterol 2010 105 : 1266 1275.
24. Nimish B, Vakil N, Huff FJ, Bian A, Jones DS, Stamler D. Arbaclofen placarbil monotherapy decreases GERD symptoms in subjects with previous PPI therapy. Gastroenterology 2009 136 (Suppl. 1): A-79.
25. Beaumont H, Smout A, Aanen M et al. The GABA(B) receptor agonist AZD9343 inhibits transient lower oesophageal sphincter relaxations and acid reflux in healthy volunteers: a phase I study. Aliment Pharmacol Ther 2009 30 : 937 946.
26. Boeckxstaens G, Beaumont H, Hatlebakk JG, Silberg DG, Adler J, Denison H. Efficacy and tolerability of the novel reflux inhibitor, AZD3355, as add-on treatment in GERD patients with symptoms despite proton pump inhibitor therapy. Gastroenterology 2009 136 (Suppl. 1 A 436.
27. Branden L, Fredriksson A, Harring E, Jensen J, Lehmann A. The novel, peripherally restricted GABAB receptor agonist lesogaberan (AZD3355) inhibits acid reflux and reduces esophageal acid exposure as measured with 24-h pHmetry in dogs. Eur J Pharmacol 2010 634 : 138 141.
28. Lehmann A, Antonsson M, Holmberg AA et al. (R)-(3-amino-2-fluoropropyl) phosphinic acid (AZD3355), a novel GABAB receptor agonist, inhibits transient lower esophageal sphincter relaxation through a peripheral mode of action. J Pharmacol Exp Ther 2009 331 : 504 512.
29. Boeckxstaens GE, Beaumont H, Mertens V et al. Effects of lesogaberan, a novel GABA(B)-receptor agonist, on reflux and lower esophageal sphincter function in patients with gastroesophageal reflux disease. Gastroenterology 2010 DOI:.
30. Page AJ, Young RL, Martin CM et al. Metabotropic glutamate receptors inhibit mechanosensitivity in vagal sensory neurons. Gastroenterology 2005 128 : 402 410.
31. Frisby CL, Mattsson JP, Jensen JM, Lehmann A, Dent J, Blackshaw LA. Inhibition of transient lower esophageal sphincter relaxation and gastroesophageal reflux by metabotropic glutamate receptor ligands. Gastroenterology 2005 129 : 995 1004.
32. Tack J. Is there a unifying role for visceral hypersensitivity and irritable bowel syndrome in non-erosive reflux disease? Digestion 2008 78 (Suppl. 1 42 5.
33. Zerbib F, Keywood C, Strabach G. Efficacy, tolerability and pharmacokinetics of a modified release formulation of ADX10059, a negative allosteric modulator of metabotropic glutamate receptor 5: an esophageal pH-impedance study in healthy subjects. Neurogastroenterol Motil 2010 DOI:.
34. Bruley Des Varannes S, Tutuian R, Roman S et al. Effect of mGLUR5 negative allosteric modulator (NAM) ADX10059, monotherapy, on reflux events and lower esophageal sphincter (LES) function in patients with gastro - esophageal reflux disease (GERD). Gastroenterology May 2010 138 (Suppl. 1) : S13.
35. Partosoedarso ER, Abrahams TP, Scullion RT, Moerschbaecher JM, Hornby PJ. Cannabinoid1 receptor in the dorsal vagal complex modulates lower oesophageal sphincter relaxation in ferrets. J Physiol 2003 550 : 149 158.
36. Beaumont H, Jensen J, Carlsson A, Ruth M, Lehmann A, Boeckxstaens G. Effect of delta9-tetrahydrocannabinol, a cannabinoid receptor agonist, on the triggering of transient lower oesophageal sphincter relaxations in dogs and humans. Br J Pharmacol 2009 156 : 153 162.
37. Scarpellini E, Vos R, Vanden BP, Tack J. Influence of the cannabinoid type 1 receptor Rimonabant on esophageal function in man. Gastroenterology 2009 136 (Suppl. 1 A 122.